Couples who have not conceived after one year of regular unprotected sexual intercourse should be offered clinical investigation, including semen analysis and assessment of ovulation.
A 29 year old nulliparous woman was referred to the radiology department by her gynaecologist for a hysterosalpingogram. She had been trying unsuccessfully to conceive for 15 months. She had no medical, surgical, or gynaecological history. She had never been pregnant. Her body mass index was normal and she was a non-smoker. She described a regular 28 day menstrual cycle, with periods-which were not heavy or painful-lasting between five and six days. She had no history of sexually transmitted diseases. Day 21 progesterone concentrations indicated that she was ovulating and her partner's semen analysis was normal. The couple were having regular intercourse. A chlamydia test was negative. Hysterosalpingography was carried out (fig 1) .
Questions
1 What is infertility?
2 How should a couple presenting with infertility be investigated?
3 How would you interpret this image?
4 What other imaging modalities can be used instead of the investigation shown?
Answers 1 What is infertility? Short answer
Infertility (clinical definition) is currently defined as one year of unwanted non-conception with unprotected intercourse in the fertile phase of the menstrual cycle.
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Long answer
Couples who have not conceived after one year of regular unprotected sexual intercourse should be offered clinical investigation, including semen analysis and assessment of ovulation.
Offer earlier investigation if the woman is aged 35 years or there is a history of predisposing factors (such as amenorrhoea, oligomenorrhoea, pelvic inflammatory disease, or undescended testes).
Couples who are worried about their fertility should be informed that 84% of couples in the general population will conceive within one year if they do not use contraception and have regular sexual intercourse. Of those who do not conceive in the first year, about half will do so in the second year (cumulative pregnancy rate 92% after two years and 93% after three years). 2 How should a couple presenting with infertility be investigated?
Short answer
Focused questioning to identify known risk factors; full examination of both partners; semen analysis in the male partner; assessment of ovulation, ovarian reserve, and tubal patency in the female partner.
Women who smoke should be informed that smoking probably reduces their fertility and men should be informed that it is associated with reduced semen quality. Both partners should be offered referral to smoking cessation programmes.
Women should be advised to drink no more than 3-4 units of alcohol a week and avoid intoxication because this can harm the developing fetus. Men should be informed that excess alcohol intake is detrimental to sperm quality.
Men should be informed of the association between raised scrotal temperature as a result of wearing tight underwear and reduced semen quality.
Couples should be informed that sexual intercourse every two to three days optimises the chance of pregnancy. Timing intercourse to coincide with ovulation causes stress and is not recommended.
Semen analysis should be carried out in the male partner and compared with World Health Organization reference values. In the United Kingdom, low sperm count or quality is found to be the only cause of infertility in about 20% of couples and is a contributory factor in a further 25% (table⇓). 4 If the result of the first semen analysis is abnormal, offer a repeat confirmatory test three months after the initial analysis to allow for a new cycle of spermatozoa formation. However, this delay may cause anxiety, and the timing of the second sample should take into consideration the man's preferences. 4 Ask women about the frequency and regularity of their menstrual cycles. Regular menstrual cycles in the range of 26-36 days are usually indicative of ovulation. 5 Anovulation and oligo-ovulation are ovulatory disorders that are estimated to cause 21% of female infertility. 4 To confirm ovulation, measure serum progesterone in the midluteal phase of a cycle (day 21 of a 28 day cycle). This test may need to be conducted later or earlier in the cycle depending on the cycle length (for example, day 28 of a 35 day cycle). 4 Tubal factors are estimated to account for 14% of cases of subfertility in women. 6 The results of semen analysis and assessment of ovulation should therefore be known before a test for tubal patency is performed.
Before undergoing uterine instrumentation women should be offered screening for Chlamydia trachomatis. If the test result is positive, women and their sexual partners should be referred for appropriate management with treatment and contact tracing. Prophylactic antibiotics should be considered before uterine instrumentation if the woman has not been screened. 4 Women who are not known to have comorbidities (such as pelvic inflammatory disease, previous ectopic pregnancy, or endometriosis) should be offered hysterosalpingography to screen for tubal occlusion. This is a radiographic contrast study used to assess patency and the anatomical structure of the uterine cavity and fallopian tubes. Hysterosalpingography can also be used to assess anatomy before uterine or tubal surgery. 7 Pathological findings that can be detected on hysterosalpingography include uterine abnormalities such as submucosal leiomyoma, endometrial polyps, endometrial carcinoma, synechiae, and adenomyosis. 8 Tubal abnormalities such as hydrosalpinx, salpingitis, tubal occlusion, and peritubal adhesions can also be detected. 9 However, the absence of peritubal adhesions does not exclude their presence and this should be reflected in the radiologist's report and information.
Women who are thought to have comorbidities-such as a history of pelvic inflammatory disease, previous ectopic pregnancy, or endometriosis-should be offered laparoscopy and dye so that tubal and other pelvic pathology can be assessed at the same time. When hysterosalpingography suggests the presence of tubal obstruction this will be confirmed by laparoscopy in only 38% of women, so this test is not a reliable indicator of tubal occlusion. In contrast, when the test suggests that the tubes are patent, this will be confirmed at laparoscopy in 94% of women, and so it is a reliable indicator of tubal patency. 10 Opinions differ as to whether hysteroscopy should be considered as a routine investigation in addition to hysterosalpingography, laparoscopy, and dye in infertile couples. A causal association between leiomyoma and infertility has not been established. 11 In women undergoing assisted reproduction, the presence of uterine leiomyoma is associated with a reduced chance of clinical pregnancy or delivery. 12 13 However, the effectiveness of surgical treatment of uterine abnormalities to enhance pregnancy rates is not established.
Ovarian reserve is an indirect assessment of the total number of primordial follicles within the ovaries, which decline with age. There are various tests and the sensitivity and specificity remain low. Testing for ovarian reserve can be useful before embarking on treatment for fertility, such as ovulation induction and in vitro fertilisation, and in women over the age of 35 years. 14 15 Indirect measurements using endocrine markers, such as day three basal serum follicle stimulating hormone (FSH), correlate well with the probability of conception in women in the infertile population, 16 17 women undergoing complex ovulation induction, and those participating in assisted reproductive technology cycles. [18] [19] [20] [21] A raised basal day three FSH correlates with reduced ovarian reserve in women over 35 years and is associated with poor pregnancy rates after treatment of ovulation induction (6% v 42%) when compared with women with normal ovarian reserve. 22 Poor pregnancy rate after assisted reproduction (2.7%) and high rate of pregnancy loss (71.4%) were also reported in women with raised basal day three FSH, regardless of age. 23 
How would you interpret this image? Short answer
Bicornuate uterine cavity with no definite septum identified. At least one of the fallopian tubes is patent, with definite contrast spill on the right. There is a suggestion of spill on the left, but it is not clearly shown on this single static image. Spill of contrast is indicative of a patent fallopian tube (fig 2) . 
Long answer
The main finding on this image is that the patient has a bicornuate uterine cavity. No definite septum is identified.
A bicornuate uterus is formed during embryogenesis. The upper part of the müllerian ducts are altered, resulting in a normal caudal part of the uterus but bifurcation of the cranial part. It is commonly referred to as a heart shaped uterus and described as having two horns at the upper part of the uterus. This abnormality is associated with an increased risk of adverse reproductive outcome, with an early miscarriage rate of 47%, 24 a preterm birth rate of 15-25%, 9 and a breech presentation at birth of 40-50%. 25 This image also shows that the patient has at least one patent fallopian tube, with definite contrast spill on the right. There is a suggestion of spill on the left, although this is not clearly shown on this single static image. Spill of contrast is indicative of a patent fallopian tube. The study was terminated at the patient's request owing to pain. It is therefore not possible to say whether more definite spill would have been shown from the left fallopian tube if the investigation had been satisfactorily completed.
What other imaging modalities can be used instead of the investigation shown? Short answer
Hysterosalpingo contrast ultrasonography and virtual hysterosalpingography using computed tomography.
Long answer
Hysterosalpingography is the gold standard imaging procedure for medical evaluation of the female pelvic organs; however, newer techniques are emerging.
Hysterosalpingo contrast ultrasonography is an ultrasound based technique that uses contrast instilled through the uterus to assess the uterus and fallopian tubes. It is a well tolerated procedure with no radiation dose to the patient's reproductive organs. 26 However it relies on operator technique, and some studies suggest this test is not as good as hysterosalpingography at detecting tubal abnormalities. 27 Virtual hysterosalpingography is a novel technique that is currently used mainly in research rather than clinical practice. This technique uses advances in multidetector computed tomography to create two and three dimensional images that can be reconstructed with virtual endoscopic views. This allows detailed and accurate assessment of cervical, uterine, and tubal abnormalities, and it can provide additional information about other pelvic structures. The risk of bleeding is reported to be lower with this technique than with conventional hysterosalpingography because cervical clamping is not needed. However, it is still an invasive procedure that requires speculum insertion and instillation of fluid into the uterus and fallopian tubes. Patients undergoing this new technique report less pain and discomfort than those undergoing conventional hysterosalpingography. The main drawback with this technique is the increased radiation dose to the patient-2.6 mSv (roughly equivalent to one year of background radiation) compared with 1 mSv for conventional hysterosalpingography. 27 Ultrasound and computed tomography both have the advantage of being able to investigate adjacent structures if needed.
Patient outcome
The patient is currently awaiting her outpatient appointment with her specialist to discuss the results of all her investigations. /mL White blood cells 15% or 30% normal forms ‡ Morphology *Grade a: rapid progressive motility (sperm moving swiftly, usually in a straight line). ‡Grade b: slow or sluggish progressive motility (sperm may be less linear in their progression). ‡Currently being reassessed by WHO. In the interim, the proportion of normal forms accepted by laboratories in the United Kingdom is either the earlier WHO lower limit of 30% or 15% based on strict morphological criteria.
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